CTRI/2024/07/070332
Not yet recruiting
未知
Assessment of efficacy of early introduction of ACE (angiotensin converting enzyme) inhibitors in treatment of congestive heart failure in children with medium sized ventricular septal defects: a single center open label randomized trial - NI
All India Institute of Medical Sciences, Patna0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- All India Institute of Medical Sciences, Patna
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All children aged 1 month to 10 years of either sex with medium sized VSD (diagnosed by 2D echo) presenting with congestive heart failure
Exclusion Criteria
- •i.Patients already on enalapril
- •ii.Patients who have already undergone surgical correction of VSD
- •iii.Patients with small and large sized VSD
- •iv.Patients with renal dysfunction or hyperkalemia
- •v.Patients with cardiogenic shock
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Efficacy of taking Aceclofenac painkiller before root canal treatment on pain after the treatment- A Clinical TrialHealth Condition 1: K044- Acute apical periodontitis of pulpal originHealth Condition 2: K041- Necrosis of pulpHealth Condition 3: K047- Periapical abscess without sinusHealth Condition 4: K040- PulpitisCTRI/2019/09/021074S Jothi Latha75
Completed
Not Applicable
Retrospective study to determine the effects of acetabular fractureExamination of the quality of life after an acetabular fractureS32.4Fracture of acetabulumDRKS00004762Berufsgenossenschaftliche UnfallklinikKlinik für Unfall- und Wiederherstellungschirurgie derEberhard-Karls-Universität Tübingen58
Active, not recruiting
Phase 1
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 20.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-005317-68-BEAcerta Pharma, BV60
Active, not recruiting
Phase 1
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-005317-68-GBAcerta Pharma B.V.60
Active, not recruiting
Phase 1
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 19.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-005317-68-ESAcerta Pharma, BV80